Stock Events

Stock Events

Acorda Therapeutics 

$0.66
46
-$0.22-24.86% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1AprExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-7.55
-4.84
-2.14
0.57
Expected EPS
N/A
Actual EPS
N/A

Financials

-214.95%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
117.63MRevenue
-252.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACOR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen offers multiple sclerosis (MS) treatments, directly competing with Acorda's MS therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis provides a range of MS treatments, including oral and infusion therapies, competing in the same space as Acorda.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical has a strong presence in the MS market with Copaxone, directly competing with Acorda's offerings.
Roche
RHHBY
Mkt Cap258.9B
Roche, with its MS drug Ocrevus, competes in the neurology space, targeting a similar patient group as Acorda.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, though more known for its HIV and hepatitis C drugs, is expanding into other areas, including potential treatments that could compete with Acorda's neurological therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes treatments for neurological disorders, potentially competing with Acorda's products.
Merck
MRK
Mkt Cap214.76B
Merck has been expanding its focus on neurodegenerative diseases, including MS, which could position it as a competitor to Acorda.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes focuses on central nervous system (CNS) disorders, with a portfolio that could compete with Acorda's neurological therapies.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca, with its broad research in various therapeutic areas, including neurology, could become a competitor as it expands its portfolio.

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Show more...
CEO
Ron Cohen
Employees
111
Country
US
ISIN
US00484M6012
WKN
000A2QLBW

Listings

0 Comments

Share your thoughts

FAQ

What is Acorda Therapeutics stock price today?▼
The current price of ACOR is $0.66 USD — it has decreased by -24.86% in the past 24 hours. Watch Acorda Therapeutics stock price performance more closely on the chart.
What is Acorda Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acorda Therapeutics stocks are traded under the ticker ACOR.
What is Acorda Therapeutics revenue for the last year?▼
Acorda Therapeutics revenue for the last year amounts to 117.63M USD.
What is Acorda Therapeutics net income for the last year?▼
ACOR net income for the last year is -252.85M USD.
How many employees does Acorda Therapeutics have?▼
As of April 01, 2026, the company has 111 employees.
In which sector is Acorda Therapeutics located?▼
Acorda Therapeutics operates in the Manufacturing sector.
When did Acorda Therapeutics complete a stock split?▼
The last stock split for Acorda Therapeutics was on June 05, 2023 with a ratio of 1:20.
Where is Acorda Therapeutics headquartered?▼
Acorda Therapeutics is headquartered in Ardsley, US.